315 related articles for article (PubMed ID: 15726525)
1. Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
Phillips GL; Abboud CN; Bernstein SH; Friedberg JW; Ifthikharuddin JJ; Lancet JE; Liesveld JL; Spreng E; Johnson V; Chapman M; Vesole DH
Semin Oncol; 2004 Dec; 31(6 Suppl 18):59-61. PubMed ID: 15726525
[TBL] [Abstract][Full Text] [Related]
2. A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Phillips GL; Bernstein SH; Liesveld JL; Abboud CN; Becker MW; Constine LS; Ifthikharuddin JJ; Loughner JE; Milner LA; Vesole DH; Friedberg JW
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1033-42. PubMed ID: 21074630
[TBL] [Abstract][Full Text] [Related]
3. The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation.
Phillips GL
Semin Oncol; 2002 Dec; 29(6 Suppl 19):53-6. PubMed ID: 12577245
[TBL] [Abstract][Full Text] [Related]
4. Results of autologous transplantation in lymphoma are not improved by increasing the dose of etoposide in the BEAM regimen: a single-centre sequential-cohort study.
Martín A; Caballero MD; Pérez-Simón JA; López-Holgado N; Mateos MV; Cañizo MC; Miguel JF
Bone Marrow Transplant; 2004 Oct; 34(8):675-82. PubMed ID: 15334049
[TBL] [Abstract][Full Text] [Related]
5. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study.
Phillips GL; Meisenberg B; Reece DE; Adams VR; Badros A; Brunner J; Fenton R; Filicko J; Grosso D; Hale GA; Howard DS; Johnson VP; Kniska A; Marshall KW; Nath R; Reed E; Rapoport AP; Takebe N; Vesole DH; Wagner JL; Flomenberg N
Biol Blood Marrow Transplant; 2004 Jul; 10(7):473-83. PubMed ID: 15205668
[TBL] [Abstract][Full Text] [Related]
6. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
Phillips GL; Meisenberg BR; Reece DE; Adams VR; Badros AZ; Brunner JL; Fenton RG; Filicko J; Grosso DL; Hale GA; Howard DS; Johnson VP; Kniska A; Marshall KW; Mookerjee B; Nath R; Rapoport AP; Sarkodee-Adoo C; Takebe N; Vesole DH; Wagner JL; Flomenberg N
Bone Marrow Transplant; 2004 Apr; 33(8):781-7. PubMed ID: 14767498
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
Hartmann JT; von Vangerow A; Fels LM; Knop S; Stolte H; Kanz L; Bokemeyer C
Br J Cancer; 2001 Feb; 84(3):313-20. PubMed ID: 11161394
[TBL] [Abstract][Full Text] [Related]
8. High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.
Ager S; Mahendra P; Richards EM; Bass G; Baglin TP; Marcus RE
Bone Marrow Transplant; 1996 Mar; 17(3):335-40. PubMed ID: 8704683
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
Alessandrino EP; Bernasconi P; Colombo A; Caldera D; Martinelli G; Vitulo P; Malcovati L; Nascimbene C; Varettoni M; Volpini E; Klersy C; Bernasconi C
Bone Marrow Transplant; 2000 Feb; 25(3):309-13. PubMed ID: 10673703
[TBL] [Abstract][Full Text] [Related]
10. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
12. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease.
Schiffman KS; Bensinger WI; Appelbaum FR; Rowley S; Lilleby K; Clift RA; Weaver CH; Demirer T; Sanders JE; Petersdorf S; Gooley T; Weiden P; Zuckerman N; Montgomery P; Maziarz R; Klarnet JP; Rivkin S; Trueblood K; Storb R; Holmberg L; Buckner CD
Bone Marrow Transplant; 1996 Jun; 17(6):943-50. PubMed ID: 8807098
[TBL] [Abstract][Full Text] [Related]
14. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[TBL] [Abstract][Full Text] [Related]
15. Pilot study of tandem high-dose chemotherapy and autologous stem cell transplantation with a novel combination of regimens in patients with poor risk lymphoma.
Papadopoulos KP; Noguera-Irizarry W; Wiebe L; Hesdorffer CS; Garvin J; Nichols GL; Vahdat LH; Lo KM; Skerrett D; Bernstein D; Sharpe E; Savage DG
Bone Marrow Transplant; 2005 Sep; 36(6):491-7. PubMed ID: 16044139
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
Ozkaynak MF; Sahdev I; Gross TG; Levine JE; Cheerva AC; Richards MK; Rozans MK; Shaw PJ; Kadota RP
J Pediatr Hematol Oncol; 2008 Mar; 30(3):204-9. PubMed ID: 18376282
[TBL] [Abstract][Full Text] [Related]
17. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
Spencer A; Horvath N; Gibson J; Prince HM; Herrmann R; Bashford J; Joske D; Grigg A; McKendrick J; Prosser I; Lowenthal R; Deveridge S; Taylor K;
Bone Marrow Transplant; 2005 May; 35(10):971-7. PubMed ID: 15778725
[TBL] [Abstract][Full Text] [Related]
18.
Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
[No Abstract] [Full Text] [Related]
19. Cytoprotection by amifostine during autologous stem cell transplantation for advanced refractory hematologic malignancies.
Gabriel DA; Shea TC; Serody JS; Moore DT; Kirby SL; Harvey D; Krasnov C
Biol Blood Marrow Transplant; 2005 Dec; 11(12):1022-30. PubMed ID: 16338625
[TBL] [Abstract][Full Text] [Related]
20. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.
Musso M; Scalone R; Marcacci G; Lanza F; Di Renzo N; Cascavilla N; Di Bartolomeo P; Crescimanno A; Perrone T; Pinto A
Bone Marrow Transplant; 2010 Jul; 45(7):1147-53. PubMed ID: 19898504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]